Repligen Corporation (RGEN)
| Market Cap | 8.34B |
| Revenue (ttm) | 734.10M |
| Net Income (ttm) | 145.81M |
| Shares Out | 55.60M |
| EPS (ttm) | 2.53 |
| PE Ratio | 59.30 |
| Forward PE | 217.39 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 330,172 |
| Open | 148.99 |
| Previous Close | 150.40 |
| Day's Range | 147.20 - 153.39 |
| 52-Week Range | 137.21 - 327.32 |
| Beta | 0.90 |
| Analysts | Buy |
| Price Target | 244.67 (+63.2%) |
| Earnings Date | Apr 27, 2022 |
About RGEN
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput...
Financial Performance
In 2021, Repligen's revenue was $670.53 million, an increase of 83.08% compared to the previous year's $366.26 million. Earnings were $128.29 million, an increase of 114.08%.
Financial StatementsAnalyst Forecast
According to 14 analysts, the average rating for RGEN stock is "Buy." The 12-month stock price forecast is 244.67, which is an increase of 63.16% from the latest price.
News
Will Repligen's (RGEN) COVID Woes Be Offset by Product Demand?
The declining pace of COVID-19 vaccination programs is likely to hurt Repligen's (RGEN) revenue growth rate in 2022. However, the strong core business is likely to offer a respite.
Repligen (RGEN) Q1 Earnings and Sales Beat Estimates, Stock Up
Repligen (RGEN) reports encouraging first-quarter results with both sales and earnings beating estimates. RGEN also reduced its financial guidance for 2022
Why Repligen Is Up More Than 10% Today
A stronger-than-expected earnings report calls months of the stock's weakness into question.
Repligen (RGEN) Beats Q1 Earnings and Revenue Estimates
Repligen (RGEN) delivered earnings and revenue surprises of 27.78% and 12.45%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Repligen Reports First Quarter 2022 Financial Results and Updates Full Year 2022 Financial Guidance
—Record revenue of $206.4 million for the quarter, and year-over-year growth of 45% as reported and 48% at constant currency
2 Reasons to Buy Repligen, and 1 Reason to Sell
Management has executed its strategy well, but a potential risk is looming.
Repligen to Report First Quarter 2022 Financial Results
Webcast and Conference Call to Be Held Wednesday, April 27, 2022 at 8:30 a.m. EDT Webcast and Conference Call to Be Held Wednesday, April 27, 2022 at 8:30 a.m. EDT
2 Top Biotech Stocks to Buy for the Long Haul
Repligen and Exact Sciences have a proven track record with significant opportunities for continued growth.
Repligen Corporation to Present at KeyBanc Life Science and MedTech Investor Forum
WALTHAM, Mass., March 18, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtua...
908 Devices Appoints Tony J. Hunt, President and CEO, Repligen, to its Board of Directors
BOSTON--(BUSINESS WIRE)--908 Devices has appointed Tony J. Hunt, President and CEO of Repligen Corporation to serve on its Board of Directors effective immediately.
Repligen (RGEN) Q4 Earnings and Revenues Surpass Estimates
Repligen's (RGEN) fourth-quarter earnings and revenues beat estimates. It expects to achieve revenue growth in the range of 19-24% in 2022.
Repligen (RGEN) Tops Q4 Earnings and Revenue Estimates
Repligen (RGEN) delivered earnings and revenue surprises of 24.62% and 3.78%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Repligen Reports Fourth Quarter and Full Year 2021 Financial Results
— Record revenue of $186.5 million for the quarter, and year-over-year growth of 72%
Medical Stocks' Q4 Earnings on Feb 17: RGEN, IRWD & More
Let us take a look at four biotech or drug companies - RGEN, IRWD, EXEL and LGND - due to release their quarterly results on Feb 16.
Repligen Launches AAV Affinity Resins for Gene Therapy Purification
AVIPure® affinity resins address the market need for high performance and caustic stability AVIPure® affinity resins address the market need for high performance and caustic stability
Repligen Corporation to Present at 11th Annual SVB Leerink Healthcare Conference
WALTHAM, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtual...
Repligen (RGEN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Repligen to Report Fourth Quarter and Full Year 2021 Financial Results
Webcast and Conference Call to Be Held Thursday, February 17, 2022 at 8:30 a.m. EST Webcast and Conference Call to Be Held Thursday, February 17, 2022 at 8:30 a.m. EST
4 Top Biotech Stocks to Gain Amid Industry Challenges
New drug approvals and development of treatments for COVID-19 should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and pipeline progress position VRTX, REGN, DVAX ...
2 Healthcare Stocks That Could Help Set You Up for Life
These two companies offer under-the-radar ways to invest in the healthcare space.
Down 16.5% in 4 Weeks, Here's Why Repligen (RGEN) Looks Ripe for a Turnaround
Repligen (RGEN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising ea...
Repligen Corporation to Present at 40th Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Dec. 30, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtual...
3 Biotech Stocks Worth Adding to Your Portfolio Next Year
Here we present three biotech companies, which are likely to perform well in 2022, backed by strong fundamentals.
Repligen (RGEN) Upgraded to Strong Buy: Here's Why
Repligen (RGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Is Repligen (RGEN) Stock Outpacing Its Medical Peers This Year?
Here is how Repligen (RGEN) and Roche Holding AG (RHHBY) have performed compared to their sector so far this year.